Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 NSCLC 2 Skin Squamous Cell Cancer 1 Recurrence 1 Brain Neoplasms 1

Interventions

Gefitinib 5 icotinib 4 Pemetrexed 4 Docetaxel 4 camrelizumab 3 apatinib 3 anlotinib 3 aflutinib 3 Erlotinib Hydrochloride 3 osimertinib 2 dacomitinib 2 Thalidomide 2 Radiosurgery 2 Drug Therapy 2 Carboplatin 2 Afatinib 2 trilaciclib 1 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 famitinib 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiofrequency Ablation 1 Microphysiological Systems 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

2 trials

Recent Start date Enrollment

Unknown × NSCLC × dacomitinib × Clear all

NCT04811001 2023-02-21

CAPLAND

Fondazione Ricerca Traslazionale

Phase 2 Unknown

NSCLC

NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡